nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—ankylosing spondylitis	0.485	1	CbGaD
Thalidomide—PTGS2—Sulfasalazine—ankylosing spondylitis	0.0522	0.156	CbGbCtD
Thalidomide—PTGS2—Triamcinolone—ankylosing spondylitis	0.0522	0.156	CbGbCtD
Thalidomide—PTGS2—Betamethasone—ankylosing spondylitis	0.0448	0.134	CbGbCtD
Thalidomide—PTGS1—Sulfasalazine—ankylosing spondylitis	0.0441	0.132	CbGbCtD
Thalidomide—CYP3A5—Sulfasalazine—ankylosing spondylitis	0.0264	0.0791	CbGbCtD
Thalidomide—PTGS2—Dexamethasone—ankylosing spondylitis	0.026	0.0779	CbGbCtD
Thalidomide—CYP1A1—Dexamethasone—ankylosing spondylitis	0.022	0.0658	CbGbCtD
Thalidomide—CYP2C19—Prednisone—ankylosing spondylitis	0.0171	0.051	CbGbCtD
Thalidomide—CYP2E1—Dexamethasone—ankylosing spondylitis	0.017	0.0508	CbGbCtD
Thalidomide—CYP3A5—Dexamethasone—ankylosing spondylitis	0.0132	0.0395	CbGbCtD
Thalidomide—CYP2C19—Dexamethasone—ankylosing spondylitis	0.0106	0.0318	CbGbCtD
Thalidomide—CYP2C9—Dexamethasone—ankylosing spondylitis	0.00885	0.0265	CbGbCtD
Thalidomide—Pomalidomide—TNF—ankylosing spondylitis	0.00327	1	CrCbGaD
Thalidomide—TNF—Cellular roles of Anthrax toxin—ANTXR2—ankylosing spondylitis	0.00257	0.0386	CbGpPWpGaD
Thalidomide—NFKB1—Interleukin-1 processing—IL1A—ankylosing spondylitis	0.0023	0.0345	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—IL23R—ankylosing spondylitis	0.00223	0.0334	CbGpPWpGaD
Thalidomide—NFKB1—IL1-mediated signaling events—IL1R2—ankylosing spondylitis	0.0019	0.0286	CbGpPWpGaD
Thalidomide—TNF—IL23-mediated signaling events—IL23R—ankylosing spondylitis	0.0017	0.0255	CbGpPWpGaD
Thalidomide—NFKB1—Interleukin-1 signaling—IL1R2—ankylosing spondylitis	0.00167	0.0251	CbGpPWpGaD
Thalidomide—NFKB1—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—CARD9—ankylosing spondylitis	0.00121	0.0182	CbGpPWpGaD
Thalidomide—NFKB1—IL17 signaling pathway—IL17A—ankylosing spondylitis	0.00102	0.0153	CbGpPWpGaD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—RUNX3—ankylosing spondylitis	0.000901	0.0135	CbGpPWpGaD
Thalidomide—NFKB1—IL1-mediated signaling events—IL1RN—ankylosing spondylitis	0.000901	0.0135	CbGpPWpGaD
Thalidomide—TNF—IL27-mediated signaling events—IL17A—ankylosing spondylitis	0.000895	0.0135	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—IL17A—ankylosing spondylitis	0.000886	0.0133	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis Modulation and Signaling—IL1R2—ankylosing spondylitis	0.000866	0.013	CbGpPWpGaD
Thalidomide—NFKB1—TNF receptor signaling pathway —TNFRSF1B—ankylosing spondylitis	0.000835	0.0125	CbGpPWpGaD
Thalidomide—TNF—IL27-mediated signaling events—IL12B—ankylosing spondylitis	0.000832	0.0125	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—IL12B—ankylosing spondylitis	0.000824	0.0124	CbGpPWpGaD
Thalidomide—TNF—Cytokines and Inflammatory Response—IL12B—ankylosing spondylitis	0.000808	0.0121	CbGpPWpGaD
Thalidomide—NFKB1—Interleukin-1 signaling—IL1RN—ankylosing spondylitis	0.000791	0.0119	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—IL1R2—ankylosing spondylitis	0.000755	0.0113	CbGpPWpGaD
Thalidomide—TNF—TGF-beta Receptor Signaling—RUNX3—ankylosing spondylitis	0.000687	0.0103	CbGpPWpGaD
Thalidomide—TNF—IL23-mediated signaling events—IL17A—ankylosing spondylitis	0.000675	0.0101	CbGpPWpGaD
Thalidomide—TNF—Overview of nanoparticle effects—CRP—ankylosing spondylitis	0.000658	0.00988	CbGpPWpGaD
Thalidomide—NFKB1—IL1-mediated signaling events—IL1A—ankylosing spondylitis	0.000648	0.00974	CbGpPWpGaD
Thalidomide—TNF—TNF receptor signaling pathway —TNFRSF1B—ankylosing spondylitis	0.000636	0.00956	CbGpPWpGaD
Thalidomide—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.000632	0.00949	CbGpPWpGaD
Thalidomide—TNF—IL23-mediated signaling events—IL12B—ankylosing spondylitis	0.000628	0.00943	CbGpPWpGaD
Thalidomide—NFKB1—CD40/CD40L signaling—CD40LG—ankylosing spondylitis	0.000616	0.00925	CbGpPWpGaD
Thalidomide—TNF—Cytokines and Inflammatory Response—IL1A—ankylosing spondylitis	0.000594	0.00892	CbGpPWpGaD
Thalidomide—TNF—Cytokines and Inflammatory Response—IL10—ankylosing spondylitis	0.000591	0.00887	CbGpPWpGaD
Thalidomide—TNF—Matrix Metalloproteinases—MMP3—ankylosing spondylitis	0.000577	0.00867	CbGpPWpGaD
Thalidomide—NFKB1—Interleukin-1 signaling—IL1A—ankylosing spondylitis	0.000569	0.00855	CbGpPWpGaD
Thalidomide—NFKB1—IL12-mediated signaling events—IL12B—ankylosing spondylitis	0.00056	0.00841	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.00053	0.00797	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000527	0.00792	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—TNFRSF1B—ankylosing spondylitis	0.000516	0.00775	CbGpPWpGaD
Thalidomide—PTGS1—Overview of nanoparticle effects—CRP—ankylosing spondylitis	0.000512	0.0077	CbGpPWpGaD
Thalidomide—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.000502	0.00753	CbGpPWpGaD
Thalidomide—NFKB1—Structural Pathway of Interleukin 1 (IL-1)—IL1A—ankylosing spondylitis	0.0005	0.00752	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis Modulation and Signaling—TNFRSF1B—ankylosing spondylitis	0.000484	0.00727	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—TNFRSF1B—ankylosing spondylitis	0.00048	0.00721	CbGpPWpGaD
Thalidomide—NFKB1—Leptin signaling pathway—IL1RN—ankylosing spondylitis	0.000478	0.00718	CbGpPWpGaD
Thalidomide—NFKB1—BCR signaling pathway—CD79A—ankylosing spondylitis	0.00046	0.0069	CbGpPWpGaD
Thalidomide—PTGS2—Fluocinonide—Methylprednisolone—ankylosing spondylitis	0.000459	0.159	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Betamethasone—ankylosing spondylitis	0.000452	0.156	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Dexamethasone—ankylosing spondylitis	0.000452	0.156	CbGdCrCtD
Thalidomide—NFKB1—IL-1 signaling pathway—IL1A—ankylosing spondylitis	0.000441	0.00663	CbGpPWpGaD
Thalidomide—PTGS2—Fluocinonide—Triamcinolone—ankylosing spondylitis	0.000441	0.153	CbGdCrCtD
Thalidomide—NFKB1—TCR Signaling Pathway—IL17A—ankylosing spondylitis	0.000435	0.00654	CbGpPWpGaD
Thalidomide—TNF—FAS pathway and Stress induction of HSP regulation—IL1A—ankylosing spondylitis	0.000417	0.00627	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—MMP3—ankylosing spondylitis	0.000408	0.00613	CbGpPWpGaD
Thalidomide—PTGS2—Overview of nanoparticle effects—CRP—ankylosing spondylitis	0.000407	0.00611	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.000404	0.00607	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—HLA-C—ankylosing spondylitis	0.000402	0.00605	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TNFRSF1B—ankylosing spondylitis	0.000393	0.00591	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	0.000392	0.00589	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000386	0.0058	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IL17A—ankylosing spondylitis	0.000368	0.00553	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	0.000366	0.0055	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—TNFRSF1B—ankylosing spondylitis	0.000366	0.00549	CbGpPWpGaD
Thalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.000361	0.00542	CbGpPWpGaD
Thalidomide—NFKB1—IL12-mediated signaling events—HLA-A—ankylosing spondylitis	0.000361	0.00542	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—IL1RN—ankylosing spondylitis	0.000357	0.00537	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.000353	0.0053	CbGpPWpGaD
Thalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.000345	0.00518	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IL12B—ankylosing spondylitis	0.000342	0.00514	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Receptor Signaling Pathway—CD79A—ankylosing spondylitis	0.000342	0.00513	CbGpPWpGaD
Thalidomide—NFKB1—Canonical NF-kappaB pathway—TNF—ankylosing spondylitis	0.000335	0.00504	CbGpPWpGaD
Thalidomide—NFKB1—EBV LMP1 signaling—TNF—ankylosing spondylitis	0.000335	0.00504	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—CRP—ankylosing spondylitis	0.000319	0.00479	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000313	0.00471	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	0.000299	0.00448	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—IL1A—ankylosing spondylitis	0.000298	0.00447	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000297	0.00447	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000294	0.00442	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000289	0.00435	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	0.000286	0.00429	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	0.000279	0.00419	CbGpPWpGaD
Thalidomide—PTGS2—Fluticasone Propionate—Methylprednisolone—ankylosing spondylitis	0.000277	0.0958	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Betamethasone—ankylosing spondylitis	0.000272	0.0943	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—ankylosing spondylitis	0.000272	0.0943	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—ankylosing spondylitis	0.000266	0.0921	CbGdCrCtD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000266	0.004	CbGpPWpGaD
Thalidomide—NFKB1—Senescence-Associated Secretory Phenotype (SASP)—IL1A—ankylosing spondylitis	0.000263	0.00395	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000263	0.00395	CbGpPWpGaD
Thalidomide—NFKB1—amb2 Integrin signaling—TNF—ankylosing spondylitis	0.000258	0.00387	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—IL1A—ankylosing spondylitis	0.000257	0.00386	CbGpPWpGaD
Thalidomide—TNF—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000255	0.00382	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.000253	0.0038	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IL1A—ankylosing spondylitis	0.000252	0.00378	CbGpPWpGaD
Thalidomide—NFKB1—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—ankylosing spondylitis	0.000251	0.00377	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IL10—ankylosing spondylitis	0.00025	0.00376	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—CD40LG—ankylosing spondylitis	0.00025	0.00376	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—CRP—ankylosing spondylitis	0.000243	0.00365	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000238	0.00357	CbGpPWpGaD
Thalidomide—NFKB1—Corticotropin-releasing hormone—TLR4—ankylosing spondylitis	0.000234	0.00352	CbGpPWpGaD
Thalidomide—PTGS1—Overview of nanoparticle effects—TNF—ankylosing spondylitis	0.000232	0.00348	CbGpPWpGaD
Thalidomide—NFKB1—MyD88:Mal cascade initiated on plasma membrane—TLR4—ankylosing spondylitis	0.00023	0.00346	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—TNF—ankylosing spondylitis	0.000229	0.00344	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.000223	0.00335	CbGpPWpGaD
Thalidomide—NFKB1—MyD88-independent cascade—TLR4—ankylosing spondylitis	0.000221	0.00332	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—HLA-A—ankylosing spondylitis	0.00022	0.00331	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	0.000218	0.00327	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	0.000216	0.00324	CbGpPWpGaD
Thalidomide—NFKB1—TWEAK Signaling Pathway—TNF—ankylosing spondylitis	0.000207	0.00311	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000203	0.00305	CbGpPWpGaD
Thalidomide—NFKB1—Activated TLR4 signalling—TLR4—ankylosing spondylitis	0.000199	0.00299	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—CD79A—ankylosing spondylitis	0.000196	0.00294	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.000193	0.0029	CbGpPWpGaD
Thalidomide—NFKB1—TNF receptor signaling pathway —TNF—ankylosing spondylitis	0.000193	0.00289	CbGpPWpGaD
Thalidomide—NFKB1—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	0.000193	0.00289	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.000192	0.00288	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000192	0.00288	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000191	0.00286	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KIR3DL1—ankylosing spondylitis	0.00019	0.00285	CbGpPWpGaD
Thalidomide—NFKB1—Toll Like Receptor 4 (TLR4) Cascade—TLR4—ankylosing spondylitis	0.000187	0.00281	CbGpPWpGaD
Thalidomide—NFKB1—Ceramide signaling pathway—TNF—ankylosing spondylitis	0.000186	0.0028	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—CD79A—ankylosing spondylitis	0.000186	0.00279	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000185	0.00277	CbGpPWpGaD
Thalidomide—PTGS2—Overview of nanoparticle effects—TNF—ankylosing spondylitis	0.000184	0.00277	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.000183	0.00274	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000181	0.00271	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KIR3DL1—ankylosing spondylitis	0.00018	0.00271	CbGpPWpGaD
Thalidomide—NFKB1—Angiopoietin receptor Tie2-mediated signaling—TNF—ankylosing spondylitis	0.00018	0.00271	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.00018	0.0027	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—TNF—ankylosing spondylitis	0.000177	0.00266	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—ankylosing spondylitis	0.000172	0.00258	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CARD9—ankylosing spondylitis	0.000171	0.00257	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000171	0.00256	CbGpPWpGaD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—TNF—ankylosing spondylitis	0.000169	0.00255	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.000168	0.00253	CbGpPWpGaD
Thalidomide—NFKB1—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000167	0.00251	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000167	0.0025	CbGpPWpGaD
Thalidomide—NFKB1—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	0.000167	0.0025	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—IL1A—ankylosing spondylitis	0.000166	0.0025	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	0.000164	0.00247	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CARD9—ankylosing spondylitis	0.000163	0.00244	CbGpPWpGaD
Thalidomide—FGFR2—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000158	0.00238	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000155	0.00233	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.00015	0.00226	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—TLR4—ankylosing spondylitis	0.000146	0.0022	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000146	0.00219	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000145	0.00218	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—TNF—ankylosing spondylitis	0.000144	0.00217	CbGpPWpGaD
Thalidomide—NFKB1—Signaling events mediated by HDAC Class I—TNF—ankylosing spondylitis	0.000138	0.00207	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000138	0.00207	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.000128	0.00193	CbGpPWpGaD
Thalidomide—NFKB1—Transcriptional regulation of white adipocyte differentiation—TNF—ankylosing spondylitis	0.000128	0.00192	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ANTXR2—ankylosing spondylitis	0.000126	0.0019	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—IL1A—ankylosing spondylitis	0.000126	0.00189	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.00012	0.0018	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.000119	0.00179	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000119	0.00179	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—TNF—ankylosing spondylitis	0.000119	0.00179	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL1R2—ankylosing spondylitis	0.000115	0.00173	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—TNF—ankylosing spondylitis	0.000115	0.00172	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000114	0.00171	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000113	0.0017	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.000113	0.0017	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—TNF—ankylosing spondylitis	0.000111	0.00166	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL1R2—ankylosing spondylitis	0.000109	0.00164	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ERAP1—ankylosing spondylitis	0.000109	0.00164	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000108	0.00162	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000105	0.00158	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ERAP1—ankylosing spondylitis	0.000104	0.00156	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000103	0.00155	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HLA-C—ankylosing spondylitis	0.000102	0.00153	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	0.000102	0.00153	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CARD9—ankylosing spondylitis	9.98e-05	0.0015	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-C—ankylosing spondylitis	9.81e-05	0.00147	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CARD9—ankylosing spondylitis	9.47e-05	0.00142	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	9.08e-05	0.00136	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TLR4—ankylosing spondylitis	9.05e-05	0.00136	CbGpPWpGaD
Thalidomide—Sweating—Methotrexate—ankylosing spondylitis	8.97e-05	0.000835	CcSEcCtD
Thalidomide—Infection—Methylprednisolone—ankylosing spondylitis	8.96e-05	0.000834	CcSEcCtD
Thalidomide—Haematuria—Methotrexate—ankylosing spondylitis	8.92e-05	0.000831	CcSEcCtD
Thalidomide—Shock—Triamcinolone—ankylosing spondylitis	8.89e-05	0.000828	CcSEcCtD
Thalidomide—Insomnia—Prednisolone—ankylosing spondylitis	8.89e-05	0.000827	CcSEcCtD
Thalidomide—Alopecia—Prednisone—ankylosing spondylitis	8.88e-05	0.000827	CcSEcCtD
Thalidomide—Shock—Methylprednisolone—ankylosing spondylitis	8.87e-05	0.000826	CcSEcCtD
Thalidomide—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	8.85e-05	0.000823	CcSEcCtD
Thalidomide—Loss of consciousness—Dexamethasone—ankylosing spondylitis	8.83e-05	0.000822	CcSEcCtD
Thalidomide—Loss of consciousness—Betamethasone—ankylosing spondylitis	8.83e-05	0.000822	CcSEcCtD
Thalidomide—Epistaxis—Methotrexate—ankylosing spondylitis	8.83e-05	0.000822	CcSEcCtD
Thalidomide—Paraesthesia—Prednisolone—ankylosing spondylitis	8.83e-05	0.000821	CcSEcCtD
Thalidomide—Tachycardia—Triamcinolone—ankylosing spondylitis	8.82e-05	0.000821	CcSEcCtD
Thalidomide—Mental disorder—Prednisone—ankylosing spondylitis	8.81e-05	0.00082	CcSEcCtD
Thalidomide—Tachycardia—Methylprednisolone—ankylosing spondylitis	8.8e-05	0.000819	CcSEcCtD
Thalidomide—Skin disorder—Methylprednisolone—ankylosing spondylitis	8.76e-05	0.000815	CcSEcCtD
Thalidomide—Malnutrition—Prednisone—ankylosing spondylitis	8.75e-05	0.000814	CcSEcCtD
Thalidomide—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	8.74e-05	0.000813	CcSEcCtD
Thalidomide—Agranulocytosis—Methotrexate—ankylosing spondylitis	8.73e-05	0.000813	CcSEcCtD
Thalidomide—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	8.72e-05	0.000811	CcSEcCtD
Thalidomide—Convulsion—Dexamethasone—ankylosing spondylitis	8.71e-05	0.00081	CcSEcCtD
Thalidomide—Convulsion—Betamethasone—ankylosing spondylitis	8.71e-05	0.00081	CcSEcCtD
Thalidomide—Hypertension—Dexamethasone—ankylosing spondylitis	8.68e-05	0.000807	CcSEcCtD
Thalidomide—Hypertension—Betamethasone—ankylosing spondylitis	8.68e-05	0.000807	CcSEcCtD
Thalidomide—Myalgia—Dexamethasone—ankylosing spondylitis	8.56e-05	0.000796	CcSEcCtD
Thalidomide—Myalgia—Betamethasone—ankylosing spondylitis	8.56e-05	0.000796	CcSEcCtD
Thalidomide—Anxiety—Dexamethasone—ankylosing spondylitis	8.53e-05	0.000793	CcSEcCtD
Thalidomide—Anxiety—Betamethasone—ankylosing spondylitis	8.53e-05	0.000793	CcSEcCtD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	8.49e-05	0.00128	CbGpPWpGaD
Thalidomide—Discomfort—Dexamethasone—ankylosing spondylitis	8.45e-05	0.000787	CcSEcCtD
Thalidomide—Discomfort—Betamethasone—ankylosing spondylitis	8.45e-05	0.000787	CcSEcCtD
Thalidomide—Hypotension—Methylprednisolone—ankylosing spondylitis	8.43e-05	0.000784	CcSEcCtD
Thalidomide—Pain—Prednisolone—ankylosing spondylitis	8.41e-05	0.000782	CcSEcCtD
Thalidomide—Hepatitis—Methotrexate—ankylosing spondylitis	8.4e-05	0.000782	CcSEcCtD
Thalidomide—Pharyngitis—Methotrexate—ankylosing spondylitis	8.34e-05	0.000776	CcSEcCtD
Thalidomide—Urinary tract disorder—Methotrexate—ankylosing spondylitis	8.3e-05	0.000772	CcSEcCtD
Thalidomide—Vision blurred—Prednisone—ankylosing spondylitis	8.25e-05	0.000768	CcSEcCtD
Thalidomide—Urethral disorder—Methotrexate—ankylosing spondylitis	8.24e-05	0.000767	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	8.24e-05	0.000766	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	8.22e-05	0.000765	CcSEcCtD
Thalidomide—Oedema—Betamethasone—ankylosing spondylitis	8.2e-05	0.000763	CcSEcCtD
Thalidomide—Oedema—Dexamethasone—ankylosing spondylitis	8.2e-05	0.000763	CcSEcCtD
Thalidomide—Insomnia—Triamcinolone—ankylosing spondylitis	8.18e-05	0.000761	CcSEcCtD
Thalidomide—Insomnia—Methylprednisolone—ankylosing spondylitis	8.16e-05	0.000759	CcSEcCtD
Thalidomide—Infection—Dexamethasone—ankylosing spondylitis	8.15e-05	0.000758	CcSEcCtD
Thalidomide—Infection—Betamethasone—ankylosing spondylitis	8.15e-05	0.000758	CcSEcCtD
Thalidomide—Ill-defined disorder—Prednisone—ankylosing spondylitis	8.12e-05	0.000756	CcSEcCtD
Thalidomide—Paraesthesia—Triamcinolone—ankylosing spondylitis	8.12e-05	0.000755	CcSEcCtD
Thalidomide—Feeling abnormal—Prednisolone—ankylosing spondylitis	8.1e-05	0.000754	CcSEcCtD
Thalidomide—Paraesthesia—Methylprednisolone—ankylosing spondylitis	8.1e-05	0.000754	CcSEcCtD
Thalidomide—Visual impairment—Methotrexate—ankylosing spondylitis	8.1e-05	0.000754	CcSEcCtD
Thalidomide—Anaemia—Prednisone—ankylosing spondylitis	8.09e-05	0.000753	CcSEcCtD
Thalidomide—Shock—Dexamethasone—ankylosing spondylitis	8.07e-05	0.000751	CcSEcCtD
Thalidomide—Shock—Betamethasone—ankylosing spondylitis	8.07e-05	0.000751	CcSEcCtD
Thalidomide—Dyspnoea—Triamcinolone—ankylosing spondylitis	8.06e-05	0.00075	CcSEcCtD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	8.06e-05	0.00121	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	8.06e-05	0.00121	CbGpPWpGaD
Thalidomide—Nervous system disorder—Dexamethasone—ankylosing spondylitis	8.04e-05	0.000749	CcSEcCtD
Thalidomide—Nervous system disorder—Betamethasone—ankylosing spondylitis	8.04e-05	0.000749	CcSEcCtD
Thalidomide—Agitation—Prednisone—ankylosing spondylitis	8.04e-05	0.000749	CcSEcCtD
Thalidomide—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	8.03e-05	0.000747	CcSEcCtD
Thalidomide—Thrombocytopenia—Betamethasone—ankylosing spondylitis	8.03e-05	0.000747	CcSEcCtD
Thalidomide—Tachycardia—Dexamethasone—ankylosing spondylitis	8e-05	0.000745	CcSEcCtD
Thalidomide—Tachycardia—Betamethasone—ankylosing spondylitis	8e-05	0.000745	CcSEcCtD
Thalidomide—Angioedema—Prednisone—ankylosing spondylitis	8e-05	0.000744	CcSEcCtD
Thalidomide—Dyspepsia—Triamcinolone—ankylosing spondylitis	7.96e-05	0.000741	CcSEcCtD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	7.95e-05	0.00119	CbGpPWpGaD
Thalidomide—Erythema multiforme—Methotrexate—ankylosing spondylitis	7.94e-05	0.000739	CcSEcCtD
Thalidomide—Dyspepsia—Methylprednisolone—ankylosing spondylitis	7.94e-05	0.000739	CcSEcCtD
Thalidomide—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	7.93e-05	0.000738	CcSEcCtD
Thalidomide—Hyperhidrosis—Betamethasone—ankylosing spondylitis	7.93e-05	0.000738	CcSEcCtD
Thalidomide—Malaise—Prednisone—ankylosing spondylitis	7.89e-05	0.000735	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—CD79A—ankylosing spondylitis	7.88e-05	0.00118	CbGpPWpGaD
Thalidomide—Vertigo—Prednisone—ankylosing spondylitis	7.86e-05	0.000732	CcSEcCtD
Thalidomide—Eye disorder—Methotrexate—ankylosing spondylitis	7.85e-05	0.000731	CcSEcCtD
Thalidomide—Syncope—Prednisone—ankylosing spondylitis	7.85e-05	0.00073	CcSEcCtD
Thalidomide—Tinnitus—Methotrexate—ankylosing spondylitis	7.83e-05	0.000729	CcSEcCtD
Thalidomide—Anorexia—Betamethasone—ankylosing spondylitis	7.82e-05	0.000728	CcSEcCtD
Thalidomide—Anorexia—Dexamethasone—ankylosing spondylitis	7.82e-05	0.000728	CcSEcCtD
Thalidomide—Urticaria—Prednisolone—ankylosing spondylitis	7.81e-05	0.000727	CcSEcCtD
Thalidomide—Cardiac disorder—Methotrexate—ankylosing spondylitis	7.8e-05	0.000726	CcSEcCtD
Thalidomide—Fatigue—Triamcinolone—ankylosing spondylitis	7.79e-05	0.000725	CcSEcCtD
Thalidomide—Fatigue—Methylprednisolone—ankylosing spondylitis	7.78e-05	0.000724	CcSEcCtD
Thalidomide—Pain—Triamcinolone—ankylosing spondylitis	7.73e-05	0.000719	CcSEcCtD
Thalidomide—Loss of consciousness—Prednisone—ankylosing spondylitis	7.69e-05	0.000716	CcSEcCtD
Thalidomide—Hypotension—Betamethasone—ankylosing spondylitis	7.66e-05	0.000713	CcSEcCtD
Thalidomide—Hypotension—Dexamethasone—ankylosing spondylitis	7.66e-05	0.000713	CcSEcCtD
Thalidomide—Angiopathy—Methotrexate—ankylosing spondylitis	7.62e-05	0.000709	CcSEcCtD
Thalidomide—Immune system disorder—Methotrexate—ankylosing spondylitis	7.59e-05	0.000706	CcSEcCtD
Thalidomide—Convulsion—Prednisone—ankylosing spondylitis	7.58e-05	0.000706	CcSEcCtD
Thalidomide—Mediastinal disorder—Methotrexate—ankylosing spondylitis	7.57e-05	0.000705	CcSEcCtD
Thalidomide—Hypertension—Prednisone—ankylosing spondylitis	7.56e-05	0.000703	CcSEcCtD
Thalidomide—Chills—Methotrexate—ankylosing spondylitis	7.54e-05	0.000702	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—CD79A—ankylosing spondylitis	7.48e-05	0.00112	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	7.47e-05	0.000695	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	7.47e-05	0.000695	CcSEcCtD
Thalidomide—Myalgia—Prednisone—ankylosing spondylitis	7.45e-05	0.000693	CcSEcCtD
Thalidomide—Arthralgia—Prednisone—ankylosing spondylitis	7.45e-05	0.000693	CcSEcCtD
Thalidomide—Feeling abnormal—Triamcinolone—ankylosing spondylitis	7.45e-05	0.000693	CcSEcCtD
Thalidomide—FGFR2—Disease—B3GNT2—ankylosing spondylitis	7.44e-05	0.00112	CbGpPWpGaD
Thalidomide—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	7.43e-05	0.000692	CcSEcCtD
Thalidomide—Anxiety—Prednisone—ankylosing spondylitis	7.43e-05	0.000691	CcSEcCtD
Thalidomide—Alopecia—Methotrexate—ankylosing spondylitis	7.42e-05	0.000691	CcSEcCtD
Thalidomide—Insomnia—Betamethasone—ankylosing spondylitis	7.42e-05	0.00069	CcSEcCtD
Thalidomide—Insomnia—Dexamethasone—ankylosing spondylitis	7.42e-05	0.00069	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	7.4e-05	0.000689	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	7.38e-05	0.000686	CcSEcCtD
Thalidomide—Paraesthesia—Betamethasone—ankylosing spondylitis	7.36e-05	0.000685	CcSEcCtD
Thalidomide—Paraesthesia—Dexamethasone—ankylosing spondylitis	7.36e-05	0.000685	CcSEcCtD
Thalidomide—Discomfort—Prednisone—ankylosing spondylitis	7.36e-05	0.000685	CcSEcCtD
Thalidomide—Mental disorder—Methotrexate—ankylosing spondylitis	7.36e-05	0.000685	CcSEcCtD
Thalidomide—Malnutrition—Methotrexate—ankylosing spondylitis	7.31e-05	0.000681	CcSEcCtD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	7.25e-05	0.00109	CbGpPWpGaD
Thalidomide—Hypersensitivity—Prednisolone—ankylosing spondylitis	7.24e-05	0.000674	CcSEcCtD
Thalidomide—Dyspepsia—Dexamethasone—ankylosing spondylitis	7.22e-05	0.000672	CcSEcCtD
Thalidomide—Dyspepsia—Betamethasone—ankylosing spondylitis	7.22e-05	0.000672	CcSEcCtD
Thalidomide—Urticaria—Triamcinolone—ankylosing spondylitis	7.18e-05	0.000668	CcSEcCtD
Thalidomide—Urticaria—Methylprednisolone—ankylosing spondylitis	7.17e-05	0.000667	CcSEcCtD
Thalidomide—Dysgeusia—Methotrexate—ankylosing spondylitis	7.16e-05	0.000667	CcSEcCtD
Thalidomide—Body temperature increased—Triamcinolone—ankylosing spondylitis	7.15e-05	0.000665	CcSEcCtD
Thalidomide—Oedema—Prednisone—ankylosing spondylitis	7.14e-05	0.000665	CcSEcCtD
Thalidomide—Abdominal pain—Methylprednisolone—ankylosing spondylitis	7.13e-05	0.000664	CcSEcCtD
Thalidomide—Decreased appetite—Betamethasone—ankylosing spondylitis	7.13e-05	0.000664	CcSEcCtD
Thalidomide—Decreased appetite—Dexamethasone—ankylosing spondylitis	7.13e-05	0.000664	CcSEcCtD
Thalidomide—Infection—Prednisone—ankylosing spondylitis	7.1e-05	0.00066	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	7.08e-05	0.000659	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	7.08e-05	0.000659	CcSEcCtD
Thalidomide—Back pain—Methotrexate—ankylosing spondylitis	7.08e-05	0.000658	CcSEcCtD
Thalidomide—Fatigue—Betamethasone—ankylosing spondylitis	7.07e-05	0.000658	CcSEcCtD
Thalidomide—Fatigue—Dexamethasone—ankylosing spondylitis	7.07e-05	0.000658	CcSEcCtD
Thalidomide—Shock—Prednisone—ankylosing spondylitis	7.03e-05	0.000654	CcSEcCtD
Thalidomide—Pain—Betamethasone—ankylosing spondylitis	7.01e-05	0.000653	CcSEcCtD
Thalidomide—Pain—Dexamethasone—ankylosing spondylitis	7.01e-05	0.000653	CcSEcCtD
Thalidomide—Nervous system disorder—Prednisone—ankylosing spondylitis	7e-05	0.000652	CcSEcCtD
Thalidomide—Tachycardia—Prednisone—ankylosing spondylitis	6.97e-05	0.000649	CcSEcCtD
Thalidomide—Skin disorder—Prednisone—ankylosing spondylitis	6.94e-05	0.000646	CcSEcCtD
Thalidomide—Hyperhidrosis—Prednisone—ankylosing spondylitis	6.91e-05	0.000643	CcSEcCtD
Thalidomide—Vision blurred—Methotrexate—ankylosing spondylitis	6.89e-05	0.000642	CcSEcCtD
Thalidomide—NFKB1—MAPK Signaling Pathway—TNF—ankylosing spondylitis	6.83e-05	0.00103	CbGpPWpGaD
Thalidomide—Anorexia—Prednisone—ankylosing spondylitis	6.81e-05	0.000634	CcSEcCtD
Thalidomide—PTGS1—Selenium Micronutrient Network—TNF—ankylosing spondylitis	6.8e-05	0.00102	CbGpPWpGaD
Thalidomide—Ill-defined disorder—Methotrexate—ankylosing spondylitis	6.79e-05	0.000632	CcSEcCtD
Thalidomide—Anaemia—Methotrexate—ankylosing spondylitis	6.76e-05	0.000629	CcSEcCtD
Thalidomide—Feeling abnormal—Betamethasone—ankylosing spondylitis	6.76e-05	0.000629	CcSEcCtD
Thalidomide—Feeling abnormal—Dexamethasone—ankylosing spondylitis	6.76e-05	0.000629	CcSEcCtD
Thalidomide—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	6.71e-05	0.000624	CcSEcCtD
Thalidomide—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	6.71e-05	0.000624	CcSEcCtD
Thalidomide—Hypersensitivity—Triamcinolone—ankylosing spondylitis	6.66e-05	0.00062	CcSEcCtD
Thalidomide—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	6.65e-05	0.000618	CcSEcCtD
Thalidomide—Malaise—Methotrexate—ankylosing spondylitis	6.6e-05	0.000614	CcSEcCtD
Thalidomide—Vertigo—Methotrexate—ankylosing spondylitis	6.57e-05	0.000612	CcSEcCtD
Thalidomide—Leukopenia—Methotrexate—ankylosing spondylitis	6.55e-05	0.000609	CcSEcCtD
Thalidomide—Urticaria—Dexamethasone—ankylosing spondylitis	6.52e-05	0.000606	CcSEcCtD
Thalidomide—Urticaria—Betamethasone—ankylosing spondylitis	6.52e-05	0.000606	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	6.51e-05	0.000606	CcSEcCtD
Thalidomide—Dizziness—Prednisolone—ankylosing spondylitis	6.5e-05	0.000605	CcSEcCtD
Thalidomide—Asthenia—Triamcinolone—ankylosing spondylitis	6.49e-05	0.000604	CcSEcCtD
Thalidomide—Abdominal pain—Dexamethasone—ankylosing spondylitis	6.48e-05	0.000603	CcSEcCtD
Thalidomide—Abdominal pain—Betamethasone—ankylosing spondylitis	6.48e-05	0.000603	CcSEcCtD
Thalidomide—Body temperature increased—Betamethasone—ankylosing spondylitis	6.48e-05	0.000603	CcSEcCtD
Thalidomide—Body temperature increased—Dexamethasone—ankylosing spondylitis	6.48e-05	0.000603	CcSEcCtD
Thalidomide—Asthenia—Methylprednisolone—ankylosing spondylitis	6.47e-05	0.000602	CcSEcCtD
Thalidomide—Insomnia—Prednisone—ankylosing spondylitis	6.46e-05	0.000601	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—CD40LG—ankylosing spondylitis	6.43e-05	0.000965	CbGpPWpGaD
Thalidomide—Paraesthesia—Prednisone—ankylosing spondylitis	6.41e-05	0.000597	CcSEcCtD
Thalidomide—Pruritus—Triamcinolone—ankylosing spondylitis	6.4e-05	0.000595	CcSEcCtD
Thalidomide—Cough—Methotrexate—ankylosing spondylitis	6.38e-05	0.000594	CcSEcCtD
Thalidomide—Pruritus—Methylprednisolone—ankylosing spondylitis	6.38e-05	0.000594	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—HLA-B—ankylosing spondylitis	6.36e-05	0.000956	CbGpPWpGaD
Thalidomide—Convulsion—Methotrexate—ankylosing spondylitis	6.34e-05	0.00059	CcSEcCtD
Thalidomide—Dyspepsia—Prednisone—ankylosing spondylitis	6.29e-05	0.000585	CcSEcCtD
Thalidomide—NFKB1—Immune System—HLA-C—ankylosing spondylitis	6.27e-05	0.000942	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ANTXR2—ankylosing spondylitis	6.27e-05	0.000941	CbGpPWpGaD
Thalidomide—Myalgia—Methotrexate—ankylosing spondylitis	6.23e-05	0.00058	CcSEcCtD
Thalidomide—Chest pain—Methotrexate—ankylosing spondylitis	6.23e-05	0.00058	CcSEcCtD
Thalidomide—Arthralgia—Methotrexate—ankylosing spondylitis	6.23e-05	0.00058	CcSEcCtD
Thalidomide—Decreased appetite—Prednisone—ankylosing spondylitis	6.21e-05	0.000578	CcSEcCtD
Thalidomide—Rash—Prednisolone—ankylosing spondylitis	6.2e-05	0.000577	CcSEcCtD
Thalidomide—Dermatitis—Prednisolone—ankylosing spondylitis	6.19e-05	0.000576	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	6.18e-05	0.000576	CcSEcCtD
Thalidomide—Diarrhoea—Methylprednisolone—ankylosing spondylitis	6.17e-05	0.000574	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	6.17e-05	0.000926	CbGpPWpGaD
Thalidomide—Fatigue—Prednisone—ankylosing spondylitis	6.16e-05	0.000573	CcSEcCtD
Thalidomide—Headache—Prednisolone—ankylosing spondylitis	6.16e-05	0.000573	CcSEcCtD
Thalidomide—Discomfort—Methotrexate—ankylosing spondylitis	6.15e-05	0.000573	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—HLA-B—ankylosing spondylitis	6.11e-05	0.000918	CbGpPWpGaD
Thalidomide—Constipation—Prednisone—ankylosing spondylitis	6.11e-05	0.000568	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—CD40LG—ankylosing spondylitis	6.1e-05	0.000916	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HLA-B—ankylosing spondylitis	6.04e-05	0.000907	CbGpPWpGaD
Thalidomide—Confusional state—Methotrexate—ankylosing spondylitis	6.02e-05	0.00056	CcSEcCtD
Thalidomide—Dizziness—Triamcinolone—ankylosing spondylitis	5.98e-05	0.000556	CcSEcCtD
Thalidomide—Dizziness—Methylprednisolone—ankylosing spondylitis	5.96e-05	0.000555	CcSEcCtD
Thalidomide—FGFR2—Immune System—HLA-C—ankylosing spondylitis	5.95e-05	0.000894	CbGpPWpGaD
Thalidomide—Infection—Methotrexate—ankylosing spondylitis	5.93e-05	0.000552	CcSEcCtD
Thalidomide—Feeling abnormal—Prednisone—ankylosing spondylitis	5.89e-05	0.000548	CcSEcCtD
Thalidomide—Asthenia—Dexamethasone—ankylosing spondylitis	5.88e-05	0.000548	CcSEcCtD
Thalidomide—Asthenia—Betamethasone—ankylosing spondylitis	5.88e-05	0.000548	CcSEcCtD
Thalidomide—Nervous system disorder—Methotrexate—ankylosing spondylitis	5.85e-05	0.000545	CcSEcCtD
Thalidomide—Thrombocytopenia—Methotrexate—ankylosing spondylitis	5.84e-05	0.000544	CcSEcCtD
Thalidomide—Gastrointestinal pain—Prednisone—ankylosing spondylitis	5.84e-05	0.000544	CcSEcCtD
Thalidomide—Nausea—Prednisolone—ankylosing spondylitis	5.84e-05	0.000543	CcSEcCtD
Thalidomide—Pruritus—Betamethasone—ankylosing spondylitis	5.8e-05	0.00054	CcSEcCtD
Thalidomide—Pruritus—Dexamethasone—ankylosing spondylitis	5.8e-05	0.00054	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—HLA-B—ankylosing spondylitis	5.8e-05	0.000871	CbGpPWpGaD
Thalidomide—Skin disorder—Methotrexate—ankylosing spondylitis	5.8e-05	0.00054	CcSEcCtD
Thalidomide—Hyperhidrosis—Methotrexate—ankylosing spondylitis	5.77e-05	0.000537	CcSEcCtD
Thalidomide—Vomiting—Triamcinolone—ankylosing spondylitis	5.75e-05	0.000535	CcSEcCtD
Thalidomide—Vomiting—Methylprednisolone—ankylosing spondylitis	5.73e-05	0.000534	CcSEcCtD
Thalidomide—Rash—Triamcinolone—ankylosing spondylitis	5.7e-05	0.00053	CcSEcCtD
Thalidomide—Dermatitis—Triamcinolone—ankylosing spondylitis	5.69e-05	0.00053	CcSEcCtD
Thalidomide—Anorexia—Methotrexate—ankylosing spondylitis	5.69e-05	0.00053	CcSEcCtD
Thalidomide—Rash—Methylprednisolone—ankylosing spondylitis	5.69e-05	0.000529	CcSEcCtD
Thalidomide—Dermatitis—Methylprednisolone—ankylosing spondylitis	5.68e-05	0.000529	CcSEcCtD
Thalidomide—Urticaria—Prednisone—ankylosing spondylitis	5.67e-05	0.000528	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—HLA-A—ankylosing spondylitis	5.66e-05	0.000851	CbGpPWpGaD
Thalidomide—Headache—Triamcinolone—ankylosing spondylitis	5.66e-05	0.000527	CcSEcCtD
Thalidomide—Headache—Methylprednisolone—ankylosing spondylitis	5.65e-05	0.000526	CcSEcCtD
Thalidomide—Abdominal pain—Prednisone—ankylosing spondylitis	5.65e-05	0.000525	CcSEcCtD
Thalidomide—Body temperature increased—Prednisone—ankylosing spondylitis	5.65e-05	0.000525	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—CRP—ankylosing spondylitis	5.63e-05	0.000845	CbGpPWpGaD
Thalidomide—Diarrhoea—Dexamethasone—ankylosing spondylitis	5.61e-05	0.000522	CcSEcCtD
Thalidomide—Diarrhoea—Betamethasone—ankylosing spondylitis	5.61e-05	0.000522	CcSEcCtD
Thalidomide—Hypotension—Methotrexate—ankylosing spondylitis	5.58e-05	0.000519	CcSEcCtD
Thalidomide—NFKB1—Immune System—IL1RN—ankylosing spondylitis	5.45e-05	0.000818	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	5.44e-05	0.000506	CcSEcCtD
Thalidomide—Dizziness—Betamethasone—ankylosing spondylitis	5.42e-05	0.000505	CcSEcCtD
Thalidomide—Dizziness—Dexamethasone—ankylosing spondylitis	5.42e-05	0.000505	CcSEcCtD
Thalidomide—PTGS2—Selenium Micronutrient Network—TNF—ankylosing spondylitis	5.4e-05	0.000811	CbGpPWpGaD
Thalidomide—Insomnia—Methotrexate—ankylosing spondylitis	5.4e-05	0.000502	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—TLR4—ankylosing spondylitis	5.39e-05	0.00081	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-A—ankylosing spondylitis	5.37e-05	0.000807	CbGpPWpGaD
Thalidomide—Nausea—Triamcinolone—ankylosing spondylitis	5.37e-05	0.0005	CcSEcCtD
Thalidomide—Paraesthesia—Methotrexate—ankylosing spondylitis	5.36e-05	0.000499	CcSEcCtD
Thalidomide—Nausea—Methylprednisolone—ankylosing spondylitis	5.36e-05	0.000499	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—CRP—ankylosing spondylitis	5.34e-05	0.000802	CbGpPWpGaD
Thalidomide—Dyspnoea—Methotrexate—ankylosing spondylitis	5.32e-05	0.000495	CcSEcCtD
Thalidomide—Somnolence—Methotrexate—ankylosing spondylitis	5.31e-05	0.000494	CcSEcCtD
Thalidomide—Hypersensitivity—Prednisone—ankylosing spondylitis	5.26e-05	0.00049	CcSEcCtD
Thalidomide—Dyspepsia—Methotrexate—ankylosing spondylitis	5.25e-05	0.000489	CcSEcCtD
Thalidomide—Vomiting—Dexamethasone—ankylosing spondylitis	5.21e-05	0.000485	CcSEcCtD
Thalidomide—Vomiting—Betamethasone—ankylosing spondylitis	5.21e-05	0.000485	CcSEcCtD
Thalidomide—Decreased appetite—Methotrexate—ankylosing spondylitis	5.19e-05	0.000483	CcSEcCtD
Thalidomide—Rash—Betamethasone—ankylosing spondylitis	5.17e-05	0.000481	CcSEcCtD
Thalidomide—Rash—Dexamethasone—ankylosing spondylitis	5.17e-05	0.000481	CcSEcCtD
Thalidomide—FGFR2—Immune System—IL1RN—ankylosing spondylitis	5.17e-05	0.000776	CbGpPWpGaD
Thalidomide—Dermatitis—Dexamethasone—ankylosing spondylitis	5.17e-05	0.000481	CcSEcCtD
Thalidomide—Dermatitis—Betamethasone—ankylosing spondylitis	5.17e-05	0.000481	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	5.15e-05	0.00048	CcSEcCtD
Thalidomide—Fatigue—Methotrexate—ankylosing spondylitis	5.15e-05	0.000479	CcSEcCtD
Thalidomide—Headache—Betamethasone—ankylosing spondylitis	5.14e-05	0.000478	CcSEcCtD
Thalidomide—Headache—Dexamethasone—ankylosing spondylitis	5.14e-05	0.000478	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	5.14e-05	0.000772	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	5.14e-05	0.000772	CbGpPWpGaD
Thalidomide—Asthenia—Prednisone—ankylosing spondylitis	5.12e-05	0.000477	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—TLR4—ankylosing spondylitis	5.12e-05	0.000769	CbGpPWpGaD
Thalidomide—Pain—Methotrexate—ankylosing spondylitis	5.1e-05	0.000475	CcSEcCtD
Thalidomide—Pruritus—Prednisone—ankylosing spondylitis	5.05e-05	0.00047	CcSEcCtD
Thalidomide—Feeling abnormal—Methotrexate—ankylosing spondylitis	4.92e-05	0.000458	CcSEcCtD
Thalidomide—Diarrhoea—Prednisone—ankylosing spondylitis	4.89e-05	0.000455	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	4.88e-05	0.000454	CcSEcCtD
Thalidomide—Nausea—Betamethasone—ankylosing spondylitis	4.87e-05	0.000453	CcSEcCtD
Thalidomide—Nausea—Dexamethasone—ankylosing spondylitis	4.87e-05	0.000453	CcSEcCtD
Thalidomide—NFKB1—Immune System—CD79A—ankylosing spondylitis	4.78e-05	0.000718	CbGpPWpGaD
Thalidomide—Urticaria—Methotrexate—ankylosing spondylitis	4.74e-05	0.000441	CcSEcCtD
Thalidomide—Dizziness—Prednisone—ankylosing spondylitis	4.72e-05	0.00044	CcSEcCtD
Thalidomide—Body temperature increased—Methotrexate—ankylosing spondylitis	4.72e-05	0.000439	CcSEcCtD
Thalidomide—Abdominal pain—Methotrexate—ankylosing spondylitis	4.72e-05	0.000439	CcSEcCtD
Thalidomide—Vomiting—Prednisone—ankylosing spondylitis	4.54e-05	0.000423	CcSEcCtD
Thalidomide—FGFR2—Immune System—CD79A—ankylosing spondylitis	4.54e-05	0.000681	CbGpPWpGaD
Thalidomide—Rash—Prednisone—ankylosing spondylitis	4.5e-05	0.000419	CcSEcCtD
Thalidomide—Dermatitis—Prednisone—ankylosing spondylitis	4.5e-05	0.000419	CcSEcCtD
Thalidomide—Headache—Prednisone—ankylosing spondylitis	4.47e-05	0.000416	CcSEcCtD
Thalidomide—Hypersensitivity—Methotrexate—ankylosing spondylitis	4.4e-05	0.000409	CcSEcCtD
Thalidomide—Asthenia—Methotrexate—ankylosing spondylitis	4.28e-05	0.000399	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—ankylosing spondylitis	4.27e-05	0.000642	CbGpPWpGaD
Thalidomide—Nausea—Prednisone—ankylosing spondylitis	4.24e-05	0.000395	CcSEcCtD
Thalidomide—Pruritus—Methotrexate—ankylosing spondylitis	4.22e-05	0.000393	CcSEcCtD
Thalidomide—Diarrhoea—Methotrexate—ankylosing spondylitis	4.08e-05	0.00038	CcSEcCtD
Thalidomide—Dizziness—Methotrexate—ankylosing spondylitis	3.95e-05	0.000367	CcSEcCtD
Thalidomide—NFKB1—Immune System—IL1A—ankylosing spondylitis	3.92e-05	0.000589	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD40LG—ankylosing spondylitis	3.9e-05	0.000585	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—B3GNT2—ankylosing spondylitis	3.9e-05	0.000585	CbGpPWpGaD
Thalidomide—Vomiting—Methotrexate—ankylosing spondylitis	3.8e-05	0.000353	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—PTGER4—ankylosing spondylitis	3.76e-05	0.000565	CbGpPWpGaD
Thalidomide—Rash—Methotrexate—ankylosing spondylitis	3.76e-05	0.00035	CcSEcCtD
Thalidomide—Dermatitis—Methotrexate—ankylosing spondylitis	3.76e-05	0.00035	CcSEcCtD
Thalidomide—Headache—Methotrexate—ankylosing spondylitis	3.74e-05	0.000348	CcSEcCtD
Thalidomide—FGFR2—Immune System—IL1A—ankylosing spondylitis	3.72e-05	0.000559	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-B—ankylosing spondylitis	3.71e-05	0.000557	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD40LG—ankylosing spondylitis	3.7e-05	0.000556	CbGpPWpGaD
Thalidomide—PTGS2—Disease—B3GNT2—ankylosing spondylitis	3.69e-05	0.000555	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTGER4—ankylosing spondylitis	3.57e-05	0.000537	CbGpPWpGaD
Thalidomide—Nausea—Methotrexate—ankylosing spondylitis	3.55e-05	0.00033	CcSEcCtD
Thalidomide—FGFR2—Immune System—HLA-B—ankylosing spondylitis	3.52e-05	0.000528	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-A—ankylosing spondylitis	3.43e-05	0.000516	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CRP—ankylosing spondylitis	3.28e-05	0.000492	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-A—ankylosing spondylitis	3.26e-05	0.00049	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TLR4—ankylosing spondylitis	3.14e-05	0.000472	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CRP—ankylosing spondylitis	3.11e-05	0.000467	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—B3GNT2—ankylosing spondylitis	3.09e-05	0.000465	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HLA-A—ankylosing spondylitis	3.01e-05	0.000452	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TLR4—ankylosing spondylitis	2.98e-05	0.000448	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—B3GNT2—ankylosing spondylitis	2.91e-05	0.000437	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	2.91e-05	0.000437	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—B3GNT2—ankylosing spondylitis	2.91e-05	0.000436	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—ankylosing spondylitis	2.88e-05	0.000433	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—B3GNT2—ankylosing spondylitis	2.74e-05	0.000412	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP3—ankylosing spondylitis	2.68e-05	0.000403	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP3—ankylosing spondylitis	2.54e-05	0.000382	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—B3GNT2—ankylosing spondylitis	2.25e-05	0.000337	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—B3GNT2—ankylosing spondylitis	2.05e-05	0.000308	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—B3GNT2—ankylosing spondylitis	1.75e-05	0.000263	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HLA-A—ankylosing spondylitis	1.49e-05	0.000224	CbGpPWpGaD
